anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

172,081-172,140 of 319,975

filter-aware
38
Data presented at Kymera R&D Day 2021. LLOQ = Lower Limit of Quantitation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
39
IRAK4 is stained red, DAPI is blue, and panCK (pan cytokeratin) is green.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
40
Data shows dose-dependent reduction in cytokine levels compared to placebo, correlated with IRAK4 degradation percentages.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
41
The table details specific adverse events (Headache, Palpitations, Nausea) with subject counts, severity, and cohort distribution.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
42
SAD = Single Ascending Dose; MAD = Multiple Ascending Dose; LLOQ = Lower Limit of Quantitation; HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
43
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
44
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
45
The slide uses a hierarchical structure where three core pillars feed into an 'Expanding capabilities' foundation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
46
The slide uses a grid layout to map drug assets against therapeutic areas (Dermatology, Respiratory, GI, Rheumatology, Hematology, Neurology, Oncology) and color-coded mechanisms of action.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
47
The slide uses a process flow diagram to map biological signaling pathways from upstream initiation to downstream clinical manifestations.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
48
Includes a biological pathway diagram and three charts demonstrating efficacy in inhibiting pNFkB, cytokines, and IRAK4 degradation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
49
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
50
The slide illustrates a biological pathway diagram showing how IRAKiMiDs degrade both IRAK4 and IMiD substrates to inhibit proliferation and survival in cancer cells.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
51
The slide uses a structured layout to contrast patient numbers with clinical disease characteristics.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
52
Includes potency metrics (DC50, EC50) and dose-response curves for multiple cell lines.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
53
Includes tumor volume growth curves and PK/PD degradation profiles.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
54
The slide demonstrates synergistic efficacy of KT-413 across three different combination therapies.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
55
The diagram illustrates a multi-arm clinical trial design with dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for various indications, including combination therapy arms.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
56
The diagram maps clinical trial inputs (left) to regulatory outcomes (right).Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
57
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
58
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
59
The slide uses a biological pathway diagram to explain the mechanism of action for a therapeutic target.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
60
The slide uses a central column to highlight patient numbers (US and ROW) for four specific disease indications, with clinical rationale on the right.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
61
The chart is a volcano plot, a common visualization in proteomics to show statistical significance vs. fold change.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
62
The slide displays two line charts showing tumor volume over time for different dosing regimens.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
63
Includes box plots for gene expression and tumor volume growth curves, plus a Kaplan-Meier survival curve.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
64
The slide uses a process flow diagram to show the progression from initial dose levels (DL1, DL2, DLx) to expansion cohorts for various cancer types and combination therapies.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
65
The slide uses a process-flow diagram to map clinical trial phases to regulatory approval outcomes.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
66
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
67
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
68
The diagram illustrates a complex signaling loop involving STAT3, cytokines, and various cell types (leukocytes, endothelial, stromal) leading to disease states.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
69
The slide uses a structured table-like layout to map diseases to patient impact metrics and scientific evidence.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
70
The slide displays bar charts for fibrosis and bone growth, and line charts for clinical scores in arthritis and EAE models, alongside a summary table for the EAE model.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
71
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
72
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
73
The slide uses a three-column structure to define the selection process: Philosophy, Target Types, and Therapeutic Profile.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
74
The slide uses a timeline-based grid to map specific assets (KT-474, KT-413, KT-253, KT-333) and future target pipelines against years 2021-2026.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
75
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
76
The chart is a waterfall plot showing dependency scores across various cell lines, illustrating that p53-wildtype cells are highly dependent on MDM2.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
77
The slide uses a biological pathway diagram to contrast two therapeutic modalities (inhibitor vs. degrader) in the context of p53 regulation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
78
The slide uses a three-part process flow (degradation -> stabilization -> killing) supported by dose-response curves and a summary table.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
79
The slide uses a biological mechanism diagram to explain the experimental results shown in the Western blots.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
80
Shows that KT-253 (degrader) induces apoptosis even after short exposure, whereas DS-3032 (SMI) does not.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
81
The slide compares tumor volume over time against biomarker expression levels (p53, p21, PUMA) following KT-253 administration.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
82
The left chart is a waterfall plot showing CRISPR sensitivity scores; the right chart is a dose-response curve comparing KT-253 and DS-3032.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
83
Uses a Venn diagram to segment potential patient populations for MDM2 degradation therapy.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
84
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
85
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
86
The slide uses a visual metaphor of a 'wedge' expanding the druggable portion of the human proteome.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
87
Uses a three-column structure to categorize target classes and corresponding TPD solutions (Heterobifunctional Degraders, Molecular Glues).Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
88
The slide uses a list-based structure to detail technical capabilities, with a sidebar legend explaining target types.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
89
The chart uses dot size to represent abundance and color to represent different ligases/targets across tissue types.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
90
The slide uses a dot plot to show expression profiles and molecular modeling to show ternary complex formation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
91
Shows Western blot data for E3 ligase expression and dose-response curves for POI degradation in cancer vs blood cells, plus in vivo viability comparison.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
92
The slide uses a horizontal process-like layout to categorize different scientific screening techniques.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
93
The slide uses a process flow diagram for the fragment-based optimization and a heatmap for the covalent ligand screening.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
94
The table demonstrates a clear progression in optimization from Degrader 1 to Degrader 4, particularly in oral bioavailability (F%) across species.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
95
The slide uses a process flow: MoA description -> Preclinical data (dog) -> Human prediction model.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
96
The slide uses a visual comparison between 'Heterobifunctional Degraders' and 'Molecular Glues' to frame the technical approach.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
97
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit